Leclaza P3T results unveiled... mPFS 20 months

By | translator Alice Kang

22.12.01 06:00:38

가나다라 0

Abstract released at ESMO ASIA 2022...presented primary results of Leclaza monotherapy

Primary endpoint mPFS 20.6 months... 11-month improvement over the control group

DoR 19.4 months... increased the possibility of extending indication as first-line treatment

The abstract data from a global Phase III trial on ‘Leclaza (lazertinib),’ the 31st homegrown novel drug developed by Yuhan Corp, has been released. In the trial, Leclaza improved progression-free survival (PFS) by 11 months compared to the existing treatment Iressa and met the primary endpoint.

The study results of LASER301 above that assessed the safety and efficacy of Leclaza as first-line treatment in EGFR (epidermal growth factor receptor) mutant-positive NSCLC were released with other major study results on the 1st at the ESMO ASIA Congress 2022.

LASER301 is a global Phase III trial that evaluated the efficacy and safety of Leclaza as first-line treatment in locally advanced or

(same@dailypharm.com)

If you want to see the full article, please JOIN US (click)